融资丨瑞凝生物完成近亿元C轮融资

Group 1 - Shanghai Ruining Biotechnology Co., Ltd. has completed nearly 100 million RMB in Series C financing, led by Fudan Science and Technology and Qiming Venture Partners, which will accelerate the clinical and commercialization of its core products [1] - The company, established in 2018, is a key player in China's "14th Five-Year Plan" for medical equipment and biomaterials, and has developed a leading medical hydrogel technology platform for innovative medical device solutions in major clinical scenarios such as tumor treatment [1] - Ruining Biotechnology has created several first-in-China and Best-in-Class products, covering multiple segments including tumor radiotherapy protection and tumor interventional embolization, and is expanding into high-potential fields like tissue filling and drug delivery [1] Group 2 - The tumor radiotherapy "absorbable isolation hydrogel" has completed domestic clinical trials and is progressing internationally, having received breakthrough medical device designation from the FDA and submitted for CE certification in Europe [1] - The tumor embolization hydrogel has been recognized as a national innovation product and is expected to replace existing embolization solutions, enhancing the safety and effectiveness of interventional treatments for patients with liver cancer [2] - The company’s core team consists of top international talents with strong R&D backgrounds and industrial experience, aiming to deepen technology platform development and address unmet clinical needs through innovative products [2] Group 3 - The founder of Ruining Biotechnology expressed gratitude for the support from shareholders, emphasizing the commitment to continuous technological breakthroughs and long-term value growth [3] - Fudan Science and Technology congratulated the company on its financing success, highlighting the team's ability to create a sustainable product matrix and the complete capability from scientific breakthroughs to industrialization [3] - The managing director of Haoyue Capital expressed confidence in the company's potential to expand in the international market, recognizing the efficiency and effectiveness of the team led by the founder [3]